Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Vaccine antigen
- Molecular classification
- Other (most accurately described as "Antigen" rather than typical receptor/enzyme families), Protein (for protein-based antigens: e.g., viral coat proteins, bacterial toxins), Polysaccharide (for carbohydrate-based antigens: e.g., bacterial capsule polysaccharides), Toxoid (inactivated toxins), Recombinant protein
01
Overview
A vaccine antigen is the specific molecule, often a protein or polysaccharide, within a vaccine that mimics a part of a pathogen and stimulates the immune system to mount a protective response without causing disease. Antigens may be derived from killed or inactivated pathogens, purified or recombinant proteins, polysaccharides, or inactivated toxins ("toxoids"). Newer vaccine platforms use genetic material (DNA or mRNA) to produce antigens in the body rather than delivering the antigen itself. Vaccine antigens form the basis for immunological memory, enabling protection against future exposures to the disease-causing organism.
- Other names
- Vaccine componentImmunogenAntigenic determinant (context-dependent: could include specific protein names, such as "Hepatitis B surface antigen" or "Influenza hemagglutinin")
02
Mechanism of action
Induction of adaptive immune response (trigger B cells and T cells to recognize and respond to the antigen); Generation of antibody response and cellular (T cell-mediated) immunity; Creation of immunological memory for future protection.
03
Biological functions
Immune response initiationAntibody productionMemory cell formation
04
Disease associations
Infection (preventive role: e.g., hepatitis B, influenza, measles, COVID-19, meningitis)Cancer (as part of emerging therapeutic vaccines—tumor antigens)Other (used mostly for prevention, sometimes for therapeutic immunomodulation)
05
Safety considerations
Allergic reactions (e.g., to traces of ingredients, such as egg protein or gelatin)Autoimmunity (theoretical risk if self antigens are used or cross-reactivity occurs)Local and systemic reactogenicity (pain, swelling, fever following vaccination)Overstimulation of the immune system (rare; generally safe in properly formulated vaccines)Specific rare events tied to certain antigens/adjuvants (e.g., Guillain-Barré syndrome with some influenza antigens)Need for booster doses for antigens with short-lived immunity
06
Interacting drugs
Adjuvants (e.g., aluminum salts, MF59, AS01, CpG ODNs, saponins, which modulate the immune response to the antigen)
1 more in the full profile.
07
Biomarkers
Antibody titers (e.g., anti-HBs for hepatitis B)Cell-mediated immunity markers (e.g., cytokine levels, T cell proliferation in response to the antigen)Seroprotection rates (used to determine vaccine efficacy)
Beyond the preview
Go deeper on Vaccine antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vaccine antigen.